202 related articles for article (PubMed ID: 7769103)
1. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.
Holvoet P; Perez G; Zhao Z; Brouwers E; Bernar H; Collen D
J Clin Invest; 1995 Jun; 95(6):2611-9. PubMed ID: 7769103
[TBL] [Abstract][Full Text] [Related]
2. The complex link between oxidised low-density lipoprotein and unstable angina.
Niccoli G; Mongiardo R; Lanza GA; Ricco A; Burzotta F; Trani C; Mazzari MA; Liuzzo G; Lombardo A; Rebuzzi AG; Holvoet P; Crea F
J Cardiovasc Med (Hagerstown); 2007 May; 8(5):387-91. PubMed ID: 17443110
[TBL] [Abstract][Full Text] [Related]
3. [Changes in serum malondialdehyde-modified low-density lipoprotein in patients with acute myocardial infarction and stable angina pectoris treated by coronary angioplasty].
Araki T; Kanaya H; Shimizu M; Mabuchi H; Kitayama M; Kanemitsu S; Takekoshi N;
J Cardiol; 2001 Aug; 38(2):55-60. PubMed ID: 11525110
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions.
Moguilevsky N; Zouaoui Boudjeltia K; Babar S; Delrée P; Legssyer I; Carpentier Y; Vanhaeverbeek M; Ducobu J
Biochem Biophys Res Commun; 2004 Oct; 323(4):1223-8. PubMed ID: 15451427
[TBL] [Abstract][Full Text] [Related]
5. Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generation.
Holvoet P; Perez G; Bernar H; Brouwers E; Vanloo B; Rosseneu M; Collen D
J Clin Invest; 1994 Jan; 93(1):89-98. PubMed ID: 8282826
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis.
Schiopu A; Bengtsson J; Söderberg I; Janciauskiene S; Lindgren S; Ares MP; Shah PK; Carlsson R; Nilsson J; Fredrikson GN
Circulation; 2004 Oct; 110(14):2047-52. PubMed ID: 15451805
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
McDowell A; Young IS; Wisdom GB
J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome.
Romero FI; Atsumi T; Tinahones FJ; Gómez-Zumaquero JM; Amengual O; Khamashta MA; Hughes GR
Arthritis Rheum; 1999 Dec; 42(12):2606-11. PubMed ID: 10616007
[TBL] [Abstract][Full Text] [Related]
9. Increase in plasma malondialdehyde-modified low-density lipoprotein in patients with atherothrombotic cerebral infarction.
Kametsu Y; Kitagawa Y; Sekiyama S; Takagi S
Tokai J Exp Clin Med; 2005 Sep; 30(3):171-6. PubMed ID: 16285608
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes.
Griffin ME; McInerney D; Fraser A; Johnson AH; Collins PB; Owens D; Tomkin GH
Diabet Med; 1997 Sep; 14(9):741-7. PubMed ID: 9300223
[TBL] [Abstract][Full Text] [Related]
11. Antibodies against human oxidized low-density lipoprotein (LDL) as markers for human plasma modified lipoproteins.
Radulescu L; Stancu C; Antohe F
Med Sci Monit; 2004 Jul; 10(7):BR207-14. PubMed ID: 15232494
[TBL] [Abstract][Full Text] [Related]
12. [Immune response against modified low-density lipoproteins in patients with non-insulin-dependent diabetes mellitus].
González M; Rojas N; Durán D; Schade A; Campos R; Milos C
Rev Med Chil; 1997 Aug; 125(8):879-85. PubMed ID: 9567390
[TBL] [Abstract][Full Text] [Related]
13. The level of malondialdehyde-modified LDL and LDL immune complexes in patients with rheumatoid arthritis.
Wang J; Hu B; Meng Y; Zhang C; Li K; Hui C
Clin Biochem; 2009 Sep; 42(13-14):1352-7. PubMed ID: 19501077
[TBL] [Abstract][Full Text] [Related]
14. Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice results from an indirect effect.
Johnston TP; Zhou X
J Cardiovasc Pharmacol; 2007 Apr; 49(4):246-52. PubMed ID: 17438410
[TBL] [Abstract][Full Text] [Related]
15. Presence of hypochlorite-modified proteins in human atherosclerotic lesions.
Hazell LJ; Arnold L; Flowers D; Waeg G; Malle E; Stocker R
J Clin Invest; 1996 Mar; 97(6):1535-44. PubMed ID: 8617887
[TBL] [Abstract][Full Text] [Related]
16. Specific recognition of malondialdehyde and malondialdehyde acetaldehyde adducts on oxidized LDL and apoptotic cells by complement anaphylatoxin C3a.
Veneskoski M; Turunen SP; Kummu O; Nissinen A; Rannikko S; Levonen AL; Hörkkö S
Free Radic Biol Med; 2011 Aug; 51(4):834-43. PubMed ID: 21683785
[TBL] [Abstract][Full Text] [Related]
17. Oxidized low-density lipoprotein levels circulating in plasma and deposited in the tissues: comparison between Helicobacter pylori-associated gastritis and acute myocardial infarction.
Kayo S; Ohsawa M; Ehara S; Naruko T; Ikura Y; Hai E; Yoshimi N; Shirai N; Tsukamoto Y; Itabe H; Higuchi K; Arakawa T; Ueda M
Am Heart J; 2004 Nov; 148(5):818-25. PubMed ID: 15523312
[TBL] [Abstract][Full Text] [Related]
18. Immunodetection of modified lipoproteins in plasma and arterial walls of patients with coronary heart disease.
Sima A; Stancu C; Starodub O; Cristea C; Simionescu M
Rom J Intern Med; 1997; 35(1-4):29-38. PubMed ID: 9562650
[TBL] [Abstract][Full Text] [Related]
19. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure.
Holvoet P; Donck J; Landeloos M; Brouwers E; Luijtens K; Arnout J; Lesaffre E; Vanrenterghem Y; Collen D
Thromb Haemost; 1996 Nov; 76(5):663-9. PubMed ID: 8950769
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences.
Fredrikson GN; Söderberg I; Lindholm M; Dimayuga P; Chyu KY; Shah PK; Nilsson J
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):879-84. PubMed ID: 12649092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
